Blue Jet Healthcare Limited Stock Bombay S.E.

Equities

BLUEJET

INE0KBH01020

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:54 2024-07-12 am EDT 5-day change 1st Jan Change
424.2 INR +1.16% Intraday chart for Blue Jet Healthcare Limited -1.05% +15.26%
Sales 2024 7.12B 85.24M Sales 2025 * 10.03B 120M Capitalization 72.79B 872M
Net income 2024 1.64B 19.62M Net income 2025 * 2.28B 27.34M EV / Sales 2024 8.89 x
Net cash position 2024 3.19B 38.16M Net cash position 2025 * 2.58B 30.92M EV / Sales 2025 * 7 x
P/E ratio 2024
40.6 x
P/E ratio 2025 *
31.5 x
Employees 407
Yield 2024
0.26%
Yield 2025 *
0.69%
Free-Float 12.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.16%
1 week-1.05%
Current month+5.01%
1 month+10.05%
3 months+8.35%
6 months+12.37%
Current year+15.26%
More quotes
1 week
400.05
Extreme 400.05
446.35
1 month
384.45
Extreme 384.45
446.35
Current year
324.45
Extreme 324.45
446.35
1 year
319.40
Extreme 319.4
446.35
3 years
319.40
Extreme 319.4
446.35
5 years
319.40
Extreme 319.4
446.35
10 years
319.40
Extreme 319.4
446.35
More quotes
Managers TitleAgeSince
Chief Executive Officer 30 15-12-07
Director of Finance/CFO - 21-10-31
Chief Tech/Sci/R&D Officer - 20-10-20
Members of the board TitleAgeSince
Director/Board Member 64 22-04-12
Director/Board Member 45 22-07-31
Director/Board Member 52 22-04-12
More insiders
Date Price Change Volume
24-07-12 424.2 +1.16% 3 931
24-07-11 419.4 -1.28% 4,358
24-07-10 424.8 -2.00% 11,877
24-07-09 433.4 +0.01% 29,459
24-07-08 433.4 +1.10% 8,516

Delayed Quote Bombay S.E., July 12, 2024 at 06:00 am EDT

More quotes
Blue Jet Healthcare Limited is an India-based specialty pharmaceutical and healthcare ingredients and intermediates company. The Company’s operations are primarily organized in three product categories: contrast media intermediates, high-intensity sweeteners, and pharma intermediates and active pharmaceutical ingredients (APIs). Contrast media are agents used in medical imaging to enhance the visibility of body tissues under X-rays, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound. Its high-intensity sweetener business includes development, manufacturing and marketing of saccharin and its salts. The Company’s contract development and manufacturing organization (CDMO) activity in the pharma intermediate and API business is primarily focused on collaborating with innovator pharmaceutical companies and multi-national generic pharmaceutical companies by providing them with pharma intermediates that serve as building blocks for APIs in chronic therapeutic areas.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
419.6 INR
Average target price
406.7 INR
Spread / Average Target
-3.08%
Consensus

Annual profits - Rate of surprise